Journal of Pharmacy And Bioallied Sciences
Journal of Pharmacy And Bioallied Sciences Login  | Users Online: 191  Print this pageEmail this pageSmall font sizeDefault font sizeIncrease font size 
    Home | About us | Editorial board | Search | Ahead of print | Current Issue | Past Issues | Instructions | Online submission

Year : 2020  |  Volume : 12  |  Issue : 2  |  Page : 124-130

Perspective, perceptions, and promulgation of biosimilars: A questionnaire-based study to assess and understand the current challenges of biosimilars to the potential and intended users

1 Central Drugs Standard Control Organization, Ghaziabad, Uttar Pradesh, India; Amity Institute of Pharmacy, Amity University, Noida, Uttar Pradesh, India
2 Central Drugs Standard Control Organization, New Delhi, India
3 Amity Institute of Pharmacy, Amity University, Noida, Uttar Pradesh, India
4 Amity Institute of Pharmacy, Amity University, Noida, Uttar Pradesh, India; Amity Institute of Indian System of Medicines, Amity University, Noida, Uttar Pradesh, India

Correspondence Address:
Mr. Krishan Kumar Bhardwaj
O/o of DDC (I), CGO Complex No-1, Central Drugs Standard Control Organization, North Zone, Ghaziabad.
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/jpbs.JPBS_11_20

Rights and Permissions

Introduction: Biosimiliar, a copy of reference biological product, is making a buzz across the globe for its upper edge therapeutic usage. According to the market research report published by P&S Intelligence, biosimilars market is expected to generate $26.7 billion revenue by 2024, advancing at a CAGR of 29.6% during the forecast period. The first biosimilar to medicine Omnitrope, was approved in Europe by EMA (European Medicines Agency) in year 2006. Till date countries like US, China, Japan, India and many more have generated regulatory guidelines for biosimilars. Aim: Current study addresses the issues and challenges faced by Industry and regulators with their potential solutions and recommendations. Materials and methods: The questionnaire having 21 important questions/comments was given to participants after explaining the purpose of the study. The response in terms of responders V/s non-responders, agree V/s disagree, yes V/s no was recorded and analyzed by descriptive statistics. Results and Discussion: The study shows the limitation regarding the qualified personnel involved in biosimilars, as approx. 91% people believe that there is lack of expertise in this field. The same can be achieved through government initiatives for bridge courses which is also strongly felt by the major (83.6%) stakeholders participated in the study.

Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded141    
    Comments [Add]    

Recommend this journal